CD3 X ROR2 DuoBody
Multiple Oncology Indications
PreclinicalActive
Key Facts
About Traverse Biotech
Traverse Biotech is a preclinical-stage biotech leveraging a unique partnership model to develop novel immunotherapies. The company identifies and licenses promising, clinically validated therapeutic platforms from international partners, sharing development risk and expertise to accelerate programs from preclinical through proof-of-concept. Its lead asset is a CD3 x ROR2 DuoBody bispecific antibody for oncology, with a broader pipeline targeting innate immunity in oncology and aging. The experienced leadership team combines deep expertise in immunology, drug development, and business strategy to execute this capital-efficient model.
View full company profile